3989 related articles for article (PubMed ID: 7059953)
41. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
Hsueh EC; Essner R; Foshag LJ; Ollila DW; Gammon G; O'Day SJ; Boasberg PD; Stern SL; Ye X; Morton DL
J Clin Oncol; 2002 Dec; 20(23):4549-54. PubMed ID: 12454111
[TBL] [Abstract][Full Text] [Related]
42. The cell-mediated immunity in patients with malignant melanoma.
Fixa B; Komárková O; Kraus Z; Simková H
Neoplasma; 1978; 25(3):353-7. PubMed ID: 683378
[TBL] [Abstract][Full Text] [Related]
43. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
Foon KA; Lutzky J; Baral RN; Yannelli JR; Hutchins L; Teitelbaum A; Kashala OL; Das R; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M
J Clin Oncol; 2000 Jan; 18(2):376-84. PubMed ID: 10637253
[TBL] [Abstract][Full Text] [Related]
44. Clinical evaluation of liposomal tumor antigen vaccines in patients with stage-III melanoma.
Phillips NC; Loutfi A; A-Kareem AM; Shibata HR; Baines MG
Cancer Detect Prev; 1990; 14(4):491-6. PubMed ID: 2224912
[TBL] [Abstract][Full Text] [Related]
45. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group.
Palmieri G; Strazzullo M; Ascierto PA; Satriano SM; Daponte A; Castello G
J Clin Oncol; 1999 Jan; 17(1):304-11. PubMed ID: 10458247
[TBL] [Abstract][Full Text] [Related]
46. In vivo delayed hypersensitivity reactions to partially purified human melanoma antigens.
Sutherland CM; Leong SP; Cooperband SR; Deckers PJ; Hornung MO; Krementz ET
J Surg Oncol; 1982 Aug; 20(4):221-6. PubMed ID: 7109625
[TBL] [Abstract][Full Text] [Related]
47. Active-specific immunization against melanoma: is the problem at the receiving end?
Monsurrò V; Wang E; Panelli MC; Nagorsen D; Jin P; Katia Z; Smith K; Ngalame Y; Even J; Marincola FM
Semin Cancer Biol; 2003 Dec; 13(6):473-80. PubMed ID: 15001166
[TBL] [Abstract][Full Text] [Related]
48. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy.
Chung MH; Gupta RK; Hsueh E; Essner R; Ye W; Yee R; Morton DL
J Clin Oncol; 2003 Jan; 21(2):313-9. PubMed ID: 12525524
[TBL] [Abstract][Full Text] [Related]
49. Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant.
Lienard D; Avril MF; Le Gal FA; Baumgaertner P; Vermeulen W; Blom A; Geldhof C; Rimoldi D; Pagliusi S; Romero P; Dietrich PY; Corvaia N; Speiser DE
J Immunother; 2009 Oct; 32(8):875-83. PubMed ID: 19752746
[TBL] [Abstract][Full Text] [Related]
50. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
51. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
Belli F; Testori A; Rivoltini L; Maio M; Andreola G; Sertoli MR; Gallino G; Piris A; Cattelan A; Lazzari I; Carrabba M; Scita G; Santantonio C; Pilla L; Tragni G; Lombardo C; Arienti F; Marchianò A; Queirolo P; Bertolini F; Cova A; Lamaj E; Ascani L; Camerini R; Corsi M; Cascinelli N; Lewis JJ; Srivastava P; Parmiani G
J Clin Oncol; 2002 Oct; 20(20):4169-80. PubMed ID: 12377960
[TBL] [Abstract][Full Text] [Related]
52. [Clinical trial of local immunomodulation with DNCB in cases of advanced melanoma of the skin].
Budzanowska E; Pawlicki M
Przegl Dermatol; 1988; 75(1):29-34. PubMed ID: 3290999
[No Abstract] [Full Text] [Related]
53. Ipilimumab in advanced melanoma: reports of long-lasting responses.
Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
[TBL] [Abstract][Full Text] [Related]
54. [Diffuse melanosis with generalized and ocular metastasis in malignant melanoma].
Ring J; Emslander C
Hautarzt; 1984 Jun; 35(6):308-12. PubMed ID: 6469636
[TBL] [Abstract][Full Text] [Related]
55. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
Punt CJ; van Herpen CM; Jansen RL; Vreugdenhil G; Muller EW; de Mulder PH
Br J Cancer; 1997; 76(2):266-9. PubMed ID: 9231931
[TBL] [Abstract][Full Text] [Related]
56. A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring.
Dummer R; Gore ME; Hancock BW; Guillou PJ; Grobben HC; Becker JC; Oskam R; Dieleman JP; Burg G
Cancer; 1995 Feb; 75(4):1038-44. PubMed ID: 7842406
[TBL] [Abstract][Full Text] [Related]
57. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
58. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
59. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.
Batliwalla FM; Bateman BA; Serrano D; Murray D; Macphail S; Maino VC; Ansel JC; Gregersen PK; Armstrong CA
Mol Med; 1998 Dec; 4(12):783-94. PubMed ID: 9990864
[TBL] [Abstract][Full Text] [Related]
60. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]